iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
8.35
-0.20 (-2.29%)
Dec 3, 2024, 9:42 AM EST - Market open
iTeos Therapeutics Employees
iTeos Therapeutics had 157 employees as of December 31, 2023. The number of employees increased by 32 or 25.60% compared to the previous year.
Employees
157
Change (1Y)
32
Growth (1Y)
25.60%
Revenue / Employee
$222,930
Profits / Employee
-$772,312
Market Cap
305.20M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 157 | 32 | 25.60% |
Dec 31, 2022 | 125 | 31 | 32.98% |
Dec 31, 2021 | 94 | 32 | 51.61% |
Dec 31, 2020 | 62 | 19 | 44.19% |
Dec 31, 2019 | 43 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Accolade | 2,400 |
Valneva SE | 676 |
COMPASS Pathways | 186 |
NeuroPace | 171 |
Nyxoah | 147 |
C4 Therapeutics | 145 |
Sanara MedTech | 108 |
Artiva Biotherapeutics | 43 |
ITOS News
- 7 days ago - iTeos to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 2 months ago - iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT - Seeking Alpha
- 2 months ago - iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 3 months ago - iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - GlobeNewsWire
- 4 months ago - iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer - GlobeNewsWire
- 5 months ago - iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism - Seeking Alpha